Evidence map›Paper›PMID 38282676›Full record

ArticleFrontiers in oncology2023

Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer.

Delfina Popiel, Aleksandra Stańczak, Monika Skupińska, Agata Mikołajczyk, Paulina Stańczak, Filip Mituła, Joanna Hucz-Kalitowska, Kinga Jastrzębska, Damian Smuga, Jakub Dominowski and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Delfina PopielPreclinical Development Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Aleksandra StańczakClinical Development Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Monika SkupińskaPreclinical Development Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Agata MikołajczykPreclinical Development Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Paulina StańczakPreclinical Development Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Filip MitułaPreclinical Development Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Joanna Hucz-KalitowskaPreclinical Development Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Kinga JastrzębskaPreclinical Development Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Damian SmugaMedicinal Chemistry Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Jakub DominowskiPreclinical Development Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Monika DelisMedicinal Chemistry Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Krzysztof MulewskiMedicinal Chemistry Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Wojciech PietruśMedicinal Chemistry Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Daria Zdżalik-BieleckaPreclinical Development Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Karolina DzwonekPreclinical Development Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Monika Lamparska-PrzybyszPreclinical Development Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Abdellah YamaniMedicinal Chemistry Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Patrycja OlejkowskaMedicinal Chemistry Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Natalia PiórkowskaMedicinal Chemistry Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Krzysztof DubielMedicinal Chemistry Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Maciej WieczorekPreclinical Development Department, Celon Pharma S.A., Kazuń Nowy, Poland.
Jerzy PieczykolanPreclinical Development Department, Celon Pharma S.A., Kazuń Nowy, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast Growth Factor Receptors (FGFRs) are a family of receptor tyrosine kinases expressed on a plethora of cell membranes. They play crucial roles in both embryonic development and adult tissue functions. There is an increasing amount of evidence that FGFR-mediated oncogenesis is mainly related to gene amplification, activating mutations, or translocation in tumors of various histological types. Dysregulation of FGFRs has been implicated in a wide variety of neoplasms, such as bladder, gastric, and lung cancers. Given their functional significance, FGFRs emerge as promising targets for cancer therapy. Here, we introduce CPL304100, an innovative and highly potent FGFR1-3 kinase inhibitor demonstrating excellent

Indexed as

CPL304110FGFRFGFR aberrationsFGFR inhibitorsolid tumortargeted therapy

Identifiers

PMID38282676
PMCPMC10811212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.